Top in endocrinology: First generic GLP-1; semaglutide offers benefits regardless of HbA1c
Click Here to Manage Email Alerts
Teva Pharmaceuticals launched the first generic GLP-1 receptor agonist, liraglutide 1.8 mg, for patients aged 10 years or older with type 2 diabetes.
“By launching an authorized generic for Victoza (liraglutide injection 1.8 mg), we are providing patients with type 2 diabetes another option for this important treatment,” Ernie Richardsen, senior vice president and head of U.S. commercial generics at Teva, said in a press release. “In addition to strengthening Teva’s diverse complex generics portfolio, we are providing the first generic GLP-1 product to the U.S. marketplace, demonstrating once again our ability to sustain a generics powerhouse.”
It was the top story in endocrinology last week.
Another top story was about new data from the SELECT trial that showed once-weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk) reduced the risk for cardiovascular events among adults with overweight or obesity and preexisting CVD. The benefits were present in participants with low- or high-range prediabetes and those with normoglycemia.
Read these and more top stories in endocrinology below:
First generic GLP-1 receptor agonist launched
Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg. Read more.
SELECT: Semaglutide provides CV benefits for adults with obesity, regardless of HbA1c
Semaglutide reduces the risk for cardiovascular events among adults with overweight or obesity and preexisting CVD, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial. Read more.
Hypercortisolism prevalent among 24% of adults with difficult-to-control type 2 diabetes
Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers. Read more.
Q&A: International consensus provides guidance for monitoring early-stage type 1 diabetes
An international consensus group has offered the first guidance for clinicians about how to monitor people who test positive for islet autoantibodies, indicating high risk for developing type 1 diabetes. Read more.
VIDEO: Obesity treatment opens ‘next chapter’ in risk-benefit of GLP-1 drug prescribing
In this video exclusive from the American Diabetes Association Scientific Sessions, Daniel J. Drucker, MD, outlines possible adverse effects of GLP-1 drugs both current and future. Watch video.